{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114234","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.982648+00:00","generated_at":"2026-06-22T08:12:48.713244+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cellectar Q3 net loss widens to $7.8M; raises $10.7M in October financing","bullets":["Net loss Q3 2022: ($7.8M) or ($1.28)/share vs ($5.8M) ($0.97)/share in Q3 2021.","Cash and equivalents $17.8M at Sep 30, 2022, down from $35.7M at Dec 31, 2021.","Closed $10.7M gross proceeds from registered direct and private placement in October.","R&D expense $5.4M (up from $3.9M) driven by Waldenstrom's macroglobulinemia pivotal trial.","Awarded $2M NCI grant to expand Phase 1 pediatric brain tumor trial to Phase 1b."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114234","json":"https://secwatch.observer/filing/0001104659-22-114234.json","markdown":"https://secwatch.observer/filing/0001104659-22-114234.md","text":"https://secwatch.observer/filing/0001104659-22-114234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/0001104659-22-114234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/tm2229607d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:12:48.713244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a340077733e6bff3c270d1a4f671efbcefaeef9","claim":"Cellectar Biosciences, Inc. reported third quarter ended September 30, 2022 results: net income ($7.8) million, EPS ($1.28) per share.","evidence_excerpt":"The net loss attributable to common stockholders for the quarter ended September 30, 2022 was ($7.8) million, or ($1.28) per share, compared to ($5.8) million, or ($0.97) per share, in the quarter ended September 30, 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/0001104659-22-114234-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"($7.8) million"},{"label":"EPS","value":"($1.28) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6e6e00c093604fc83f06f49f4ca692cf4bb05264","claim":"Cellectar Biosciences, Inc. reported nine months ended September 30, 2022 results: net income ($21.4) million, EPS ($3.50) per share.","evidence_excerpt":"the loss attributable to common stockholders for the nine months ended September 30, 2022 was ($21.4) million, or ($3.50) per share, compared to ($18.2) million, or ($3.39) per share, in 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922114234/0001104659-22-114234-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2022"},{"label":"Net income","value":"($21.4) million"},{"label":"EPS","value":"($3.50) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}